TO THE EDITOR
NF-kB/Rel transcription factors control several apoptosis-regulating genes, and substantial evidence that NF-kB/Rel inhibitors can improve apoptotic response to therapy in many experimental tumour models establishes NF-kB/Rel blocking as a promising adjuvant approach in chemotherapy. [1] [2] To this end, the ability of NF-kB/Rel inhibitors to either induce spontaneous or enhance drugtriggered apoptosis in specific neoplasias deserves careful investigation. Some reports document the regulatory activity of NF-kB/Rel factors in human primary lymphocytic 3, 4 or myeloblastic 5, 6 leukaemias. In order to evaluate NF-kB/Rel-targeting approaches for leukaemia therapy and/or bone marrow purging, the role of this transcription factor in sustaining normal haematopoietic progenitor cell survival also needs to be evaluated. In this respect, findings obtained with different inhibitors (nuclear localisation signalcompeting peptides, decoy oligonucleotides or proteasome inhibitors) of NF-kB/Rel activity in CD34 + normal progenitors are conflicting, [6] [7] [8] possibly because of the effects of some of these inhibitors on apoptosis-regulating molecules different from NF-kB/ Rel. 9 Here, we report a comparison of the effects of NF-kB/Relspecific inhibitors on spontaneous or etoposide-induced apoptosis in AML and normal cord blood CD34 + cells, respectively. We initially analysed the effect of etoposide in Jurkat cells transfected with either an IkBa-hyperexpressing or a control void pCMVbased vector. While the drug induced in control cells an increase in NF-kB/Rel nuclear levels, these were highly reduced in IkBahyperexpressing cells; in parallel with such reduction, we observed a marked increase of the apoptotic response to etoposide (Figure 1 ).
Subsequently, we compared the effects of phosphorothioate decoy oligodeoxynucleotides (ODNs), able to specifically downmodulate NF-kB/Rel nuclear levels and transcription of target genes, 3, 5, 8 on the spontaneous or etoposide-induced apoptosis of cord blood CD34 + progenitors or AML (M0-M1, M2, M4) cells. Since primary cell samples were heterogeneous in their sensitivity threshold to etoposide (data not shown), we used an higher concentration (5 mg/ml) of the drug, compared to that used in the experiments with Jurkat cells. The results are shown in Figures 2 and 3. The nuclear levels of NF-kB/Rel were very low in unstimulated CD34 + cells and appeared to be increased by cell incubation with etoposide; decoy, but not control, ODN highly reduced the NF-kB/ Rel nuclear activity (Figure 2, a panel) . On the other hand, NF-kB/ Rel nuclear activity was constitutively present in AML cells; also in this case, addition of NF-kB/Rel-specific, but not of control scrambled, ODNs were able to downmodulate NF-kB/Rel nuclear levels ( Figure 3, a panel) . NF-kB/Rel-specific decoy oligonucleotides did not apparently affect the basal survival of either CD34 + progenitors or AML cells, but instead similarly enhanced the apoptotic response of these cell types to etoposide; control scrambled oligonucleotides did not modify cell apoptotic response in any case ( Figure 2 , b panel; Figure 3 , b and c panels).
Statistical analysis of the results was performed by paired Student's t-test: two series of samples were compared: the first was constituted by the values of etoposide-induced apoptotis in each CD34 preparation; the second set was the same as the first after addition of kB-decoy ODN.
These results are in accord with previous observations from our laboratory concerning the lack of effect of NF-kB/Rel-specific decoy oligonucleotides on the basal survival of CD34 + progenitors, 8 primary AML 5 or B-CLL 3 cells. On the other hand, such decoy oligos enhanced the apoptotic response of AML cells to cytosine arabinoside.
5 Similarly, the inhibition of NF-kB/Rel did not result in spontaneous cell apoptosis, but enhanced the response to camptothecin, in fibrosarcoma cells xenografted in SCID mice. 10 These findings indicate that in either CD34
+ cord blood, B-CLL, AML cells, or fibrosarcoma cells, NF-kB/Rel activity may not be required for sustaining basal cell survival. The role of NF-kB/Rel might be to induce molecules (IAPs, etc) that block the apoptosis process. In those neoplastic cells, including AML cells, that express constitutive high levels of NF-kB/Rel activity, 5-6 this could contribute to the Jurkat cells, stably transfected with a pCMV-based construct overexpressing the NF-kB/Rel inhibitor IkBa or a void vector, 11 were incubated with etoposide (2 mg/ml) in 10% FCS-RPMI 1640 medium. After a 3 h incubation, nuclear extracts were analysed with a NF-kB/Rel-specific oligonucleotide in EMSA; the bands indicated by the arrow correspond mainly to p50/p65 dimers.
11 In parallel, the percentages of apoptotic cells in the cultures were determined after 24 h incubation by propidium staining and flow cytometry. Correspondence transformed state by contrasting apoptogenic attacks, such as those delivered by the immune system or by chemotherapy. The extensive investigation of these mechanisms could be of relevance for a comprehensive understanding of leukaemia pathogenesis and for facing the problem of chemoresistance. Finally, the enhancement of CD34 + cell apoptotic response to chemotherapeutic compounds by NF-kB/Rel inhibitors suggests that their use as adjuvants in chemotherapy could imply a reduction of the haematopoietic cell survival and a delay in bone marrow recovery. These informations might help managing undesirable events and obtain the best therapeutic results. (a) CD34 + cells isolated from cord blood 8 were incubated with etoposide (5 mg/ml), in the presence or absence of or kB-decoy or scrambled ODN (5 mM), for 6 h; then nuclear extracts were obtained and analysed for their binding to NF-kB or SP1 (as a control) ODNs in EMSA.
5,8 (b) Six samples of CD34 + cells were incubated in 10% FCS-RPMI 1640 medium, in the absence or presence of etoposide (5 mg/ml) and/or kB-decoy or scrambled ODN (5 mM). After 68 h incubation, the percentages of apoptotic cells in the cultures were determined by propidium iodide staining and flow cytometry. 
The presence of the major chromosomal translocations, that is, t(12;21), t(1;19), t(9;22) and t(4;11) defines clinicopathological subgroups of childhood precursor B-cell ALL (ALL), which represent about 30% of all cases in USA/Europe. 1 Furthermore, these translocations have been used in risk stratification for treatment purposes.
2 However, their relative distribution and prognostic value in other geographic regions are sparse.
Stratification of pediatric precursor B-cell ALL in India using standard clinical criteria suggested that an unusually large fraction of these patients fall into a high-risk disease category.
3 This may either be a result of late diagnosis or the low-risk subgroups are under-represented in these children or a combination of both. It is possible that the distribution of molecular subtypes is not uniform in different World regions. It is also possible that gene-environment interactions, which are critical in leukemogenesis, may differently contribute in defining the relative proportions of molecular subgroups in different geographic regions.
We have therefore studied 259 newly diagnosed children with precursor B-cell ALL from India. In all, 201 consecutive samples were obtained from Tata Memorial Hospital, Mumbai and 58 ALL samples were available at All India Institute for Medical Sciences, New Delhi. Patients were o1-21 years old (63% were in the 1-9 range) with a median age of 7 years. Male-to-female ratio was 2.9:1. Only 23% of the patients presented with WBC X50 Â 10 9 /l (Table 1) . cDNAs were prepared from frozen samples; their quality and integrity were tested by RQ-RT-PCR for GAPDH using the LightCycler instrument (Roche, Mannheim, Germany). The presence of the four translocations was assayed by real-time multiplex RT-PCR as described.
4 Leukemia-specific chimeric transcripts were detected in 50 of the 259 samples (19%). In all, 18 (7%) carried a t(12;21); only one of them corresponded to the variant isoform that juxtaposes exon 5 of TEL to exon 3 of AML1. A total of 18 samples (7%) demonstrated a t(1;19), while 14 (5%) showed a t(9;22) (ALLtype, p190). The absence of t(4;11) was remarkable since the primers used would amplify 85% of all known MLL-AF4 variants. Of the 209 samples without any of the four translocations analyzed, we had enough DNA from 50 samples to analyze other 11q23 abnormalities. Southern blot analyses identified two patients carrying a rearrangement in the MLL gene (4%). Table 1 summarizes molecular and clinical data from Indian patients. We compared these results with data compiled from publications from USA/Europe (Table 2 ). Similar to the West, patients carrying BCR-ABL or E2A-PBX1 are older than patients carrying TEL-AML1 and the latter subgroup was associated with the lowest WBC. However, other differences were evident. The four translocation subgroups together represented 19% of all Indian precursor B-cell ALLs whereas in the West these ALLs, represent as much as 35%. The frequency of the TEL-AML1 subgroup in India was significantly lower than in USA or Europe (Po0.005). In contrast, the other two translocations associated with an intermediate [t(1;19)] or poor prognosis [t(9;22) ] are more commonly seen in India than in the West (Po0.005). It is still possible that rare Table 1 Relative proportions and clinical characteristics of the molecular subgroups of Indian childhood ALL
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